(Q48635335)

13 February 2018

title

A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. (English)

1 reference

13 February 2018

1 reference

1

1 reference

13 February 2018

author name string

Imbert C

2

1 reference

13 February 2018

Deloire X

3

1 reference

13 February 2018

Bioulac B

4

1 reference

13 February 2018

Gross CE

5

1 reference

13 February 2018

language of work or name

English

0 references

publication date

1 August 1997

1 reference

13 February 2018

published in

Brain Research

1 reference

13 February 2018

volume

766

1 reference

13 February 2018

issue

1-2

1 reference

13 February 2018

page(s)

107-112

1 reference

13 February 2018

Parkinson's disease: pathophysiology

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Presymptomatic revelation of experimental parkinsonism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Biochemistry of Parkinson's disease with special reference to the dopaminergic systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Parkinsonism: onset, progression, and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Distribution of Catecholamines in the Ventral Mesencephalon of Human Brain, with Special Reference to Parkinson's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine to monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Core assessment program for intracerebral transplantations (CAPIT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Neuronal basis of the parkinsonian resting tremor: a hypothesis and its implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Striatal dopamine deficiency in Parkinson's disease: role of aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

MPTP-induced parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Tremor in MPTP-induced parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2897%2900531-3

10.1016/S0006-8993(97)00531-3

7 January 2021

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018